16th CROI Debate

Presented by the Johns Hopkins University School of Medicine

Supported by an educational grant from Merck & Co.

System Requirements

The following are required to view these programs:

• OS X or later
• Safari/Mozilla 1.5

• Flash Player 9
• Broadband (Cable/DSL or higher)

To View the Program Online,
Please Read the Following Information
and Scroll Down to the bottom of the Page

About the Program

• Program Overview
• Learning Objectives
• Intended Audience
• Accreditation Statement
• Credit Designation Statement
• Course Director and Moderator
• Faculty
• Instructions for Obtaining Continuing Medical Education Credit
• Faculty Disclosure

Program Overview 

This program will use an interactive, roundtable format, featuring 2 nationally known HIV thought leaders, to discuss important issues surrounding the choices clinicians can make regarding ARV therapies and ARV therapy strategies. The discussion will provide participants with education regarding all important clinical trials to date that examine ARV agents and strategies, including those presented at the 16th CROI, and will challenge participants to re-examine their beliefs and theories on viral efficacy, tolerability, safety and the contribution of various factors to long term virologic control and preservation of future treatment options.

The information in this educational activity was planned and produced in accordance with ACCME Essentials.  All content was prepared by a distinguished faculty.  This program is for health care providers who treat HIV-positive patients, there are no prerequisites. 

Presented By:

Back to Top

Learning Objectives

At the conclusion of this activity, the participant should be able to:

1. Integrate and discuss the clinical use and balancing of drug, regimen and patient characteristics that have been demonstrated in clinical trials to be predictive of ARV treatment success

2. Analyze current clinical trial data on treatment of  ARV-naïve  and ARV-experienced patients and use this information to select ARV drugs and regimens that maximize the chance for virologic success, avoidance of toxicity and long-term adverse events and minimize the risk of loss of future treatment options.

3. Incorporate into clinical decisions the differences between various classes of ARVs, and different ARV agents within classes, regarding virologic and immunologic efficacy, safety and likelihood of resistance.

4. Describe and explain the key new clinical trials on ARV therapy and ARV therapy strategies presented at the 16th CROI.

Release Date: May 12, 2009
Expiration Date: May 12, 2010

Estimated time to complete this activity: 2 hours

Back to Top

Intended Audience

This activity is intended for physicians, physicians' assistants, and advanced practice nurses and other healthcare professionals involved in the treatment and management of patients with HIV infection. There are no prerequisites.

Back to Top

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Back to Top

Credit Designation Statement

The John Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of the CME activity.

Course Directors

John Bartlett, MD
Professor, Johns Hopkins School of Medicine
Baltimore, Maryland 

Calvin J. Cohen, MD, MS
Research Director, CRI New England,
Clinical Instructor, Harvard Medical School
Boston, Massachusetts

Faculty

Rafael E. Campo, MD
Professor of Clinical Medicine
Division of Infectious Diseases
University of Miami School of Medicine
Jackson Memorial Hospital
Miami, Florida 

Eric Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, California

Edwin DeJesus, MD
Medical Director,
Orlando Immunology Center
Orlando, Florida

Richard A. Elion, MD
Associate Professor of Clinical Medicine,
George Washington University Medical Center
Washington, DC

Ian Frank, MD
Associate Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania

Trevor Hawkins, MD
Associate Professor, University of New Mexico
Medical Director, Southwest CARE Center
Santa Fe, New Mexico

Graeme J. Moyle, MD, MB, BS
Associate Director of HIV Research,
Chelsea & Westminster Hospital
London, England

Luther A. Virgil, Jr., MD
Chief Medical Officer,
National Minority Clinical Research Association (NMCRA)
Fairfield, New Jersey

Instructions for Obtaining Continuing Medical Education Credit

In order to receive credit, participants must view the entire activity and complete a post test and activity evaluation online. Upon a successful score of 70% on the post test and completion of the evaluation, participants may print out their certificate. CME credit is available to US physicians only. Participants may access the post test and evaluation by clicking the link below:

Post Test/Evaluation 

Back to Top

Faculty Disclosure

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following disclosure information:   

Dr. John Bartlett:

• Sources of Funding for Research: None.
• Consulting Agreements: Johnson & Johnson; Tibotec; Merck & Co.
• Honorarium Agreements: Abbott; Merck & Co.
• Speakrs' Bureau: None.
• Financial Interests/Stock Ownership: None.
• Other: DSMB; Tibotec.

Dr. Calvin Cohen:

• Sources of Funding for Research: GlaxoSmithKline; Bristol-Myers Squibb; Gilead; Tibotec; Pfizer; Merck & Co.
• Consulting Agreements: GlaxoSmithKline; Bristol-Myers Squibb; Gilead; Tibotec; Pfizer; Merck & Co.; Virco.
• Speakers' Bureau/Honorarium Agreements: GlaxoSmithKline; Bristol-Myers Squibb; Gilead; Tibotec; Pfizer; Merck & Co.
• Financial Interests/Stock Ownership: None.
• Other: None.

Dr. Rafael Campo:

• Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead;
  GlaxoSmithKline; Merck; Pfizer
• Consulting Agreements: Abbott; Merck; Tibotec; Vicro
• Speakers' Bureau/Honorarium Agreements: Abbott; Gilead; Merck; Pfizer;
  Tibotec; Virco
• Financial Interests/Stock Ownership: Wife is an employee of Merck
• Other: Dr. Campo's wife is a Manager with Merck's Health Management
  Services group for Tennessee, Louisiana, Florida, and Puerto Rico. She is
  responsible for the asthma and diabetes disease areas; however, she does not
  have responsibility for any of Merck's anit-infective, antiviral, or vaccine
  products

Dr. Eric Daar:

• Sources of Funding for Research: Abbott; Merck; GlaxoSmithKline; Pfizer
• Consulting Agreements: Shering Plough; Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Pathway Diagnostics; Tibotec
• Speakers' Bureau/Honorarium Agreements: None.
• Financial Interests/Stock Ownership: None
• Other: DSMB for Arden Biosciences

Dr. Edwin DeJesus:

• Sources of Funding for Research: Abbott; Achillion; Avexa, Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GSK; Hoffman LaRoche; Merck & Co.; Pfizer; Schering Plough; Taimed; Tobira; Tibotec; Vertex.
• Consulting Agreements/Honoarium: Bristol-Myers Squibb; Gilead; GlaxoSmithKline;
  Merck & Co.; Tibotec; Vertex.
• Speakers' Bureau: Gilead; Merck & Co.; Tibotec; Virco.
• Financial Interests/Stock Ownership: None
• Other: None

Dr. Richard A. Elion:

• Sources of Funding for Research: Bristol-Myers Squibb; Gilead;
  GlaxoSmithKline; Incyte; Tibotec; Taimed.
• Consulting Agreements: Bristol-Myers Squibb Company; Gilead Sciences, Inc.;
  GlaxoSmithKline; Incyte; Panacos.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead; GSK; Tibotec.
• Financial Interests/Stock Ownership: None.
• Other: ViralEd, LLC.

Dr. Ian Frank:

• Sources of Funding for Research: Bavarian Nordic; Merck; Tibotec.
• Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead;
  GlaxoSmithKline; Pfizer; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb;
  Gilead; GlaxoSmithKline; Pfizer; Tibotec.
• Financial Interests/Stock Ownership: None.
• Other: None.

Dr. Trevor Hawkins:

• Sources of Funding for Research: Gilead; GlaxoSmithKline; Pfizer; NAPO
• Consulting Agreements: Gilead; Bristol-Myers Squibb; Merck & Co.; Virco; Pfizer; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Gilead; GlaxoSmithKline; Bristol-Myers Squibb; Merck & Co.; Pfizer; Tibotec, Virco.
• Financial Interests/Stock Ownership: None
• Other: None

Dr. Graeme Moyle:

• Sources of Funding for Research: Ardea Biosciences; Abbott; Bristol-Myers Squibb; GlaxoSmithKline; Gilead; Merck; Pfizer; Thera Technologies; Tibotec.
• Consulting Agreements: Ardea Biosciences; Bristol-Myers Squibb; GlaxoSmithKline; Gilead; Merck; Pfizer; Tobira; Thera Technologies; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Boehringer-
  Ingelheim; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
• Financial Interests/Stock Ownership: None.
• Other: None.

Dr. Luther Virgil:

• Sources of Funding for Research: None
• Consulting Agreements: Abbott; Gilead
• Speakers' Bureau/Honorarium Agreements: Abbot; Gilead
• Financial Interests/Stock Ownership: None
• Other: None

*This presentation will included information on studies and data presented at the 16th CROI involving off-label uses of efavirenz, tenofovir, emtricitabine, atazanavir, raltegravir, interleukin-2, GS-9350, SPI-452 and rosiglitazone*

Back to Top

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.

Back to Top

Copyright © 2008 The Johns Hopkins University School of Medicine. All rights reserved.